Skip to content
MatchScript
Menu

Evidence review

Ozempic vs. Wegovy, Mounjaro vs. Zepbound: Same Drug, Different Brand

Ozempic and Wegovy are the same molecule; so are Mounjaro and Zepbound. Here's exactly what differs — indication, dose, and why it matters for you.

By The MatchScript Team, Matching & Recommendations Desk

Four brand names, two molecules — and the confusion is understandable, because the pairs really are the same active drug marketed two different ways. Here's exactly what's identical, what's different, and why it actually matters which one your provider prescribes.

Semaglutide: Ozempic and Wegovy are the same molecule

Ozempic and Wegovy both contain semaglutide, made by the same manufacturer, Novo Nordisk. The difference is the approved indication and, correspondingly, the labeled dose. Ozempic is approved to improve glycemic control in adults with type 2 diabetes, to reduce cardiovascular risk in adults with type 2 diabetes and established heart disease, and to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease — it is not FDA-approved for weight loss1. Wegovy is approved specifically for chronic weight management in adults and adolescents with obesity, for adults with overweight plus a weight-related condition, to reduce cardiovascular risk in adults with established heart disease and obesity or overweight, and — as of a newer indication — to treat a form of fatty liver disease called MASH2. Wegovy's approved maintenance dose (2.4 mg) is also higher than Ozempic's standard doses, reflecting its weight-management indication21. In practice, this is why some people report a doctor prescribing Ozempic "off-label" for weight loss — it's the identical drug, just approved and dosed for a different primary purpose.

Tirzepatide: Mounjaro and Zepbound are the same molecule

The same pattern holds for Eli Lilly's tirzepatide. Mounjaro is approved to improve glycemic control in adults and adolescents 10 and older with type 2 diabetes, and is not FDA-approved for weight loss3. Zepbound is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and — a newer indication — to treat moderate to severe obstructive sleep apnea in adults with obesity4. As with semaglutide, this is genuinely one molecule sold under two names for two approved purposes, and dose ranges are labeled the same way (up to 15 mg maintenance) across both34.

Why the distinction actually matters

Three practical reasons this isn't just brand trivia. First, insurance: a plan is far more likely to cover Ozempic for a diabetes diagnosis than Wegovy for weight loss alone, which is a major reason some people end up on the "diabetes" brand of the molecule they actually want for weight management — see our insurance coverage guide for how that plays out. Second, indication-specific safety data: Wegovy and Zepbound each carry an FDA-approved indication (cardiovascular risk reduction, sleep apnea, MASH) that was proven in trials run specifically on that brand's use case, not automatically assumed from the diabetes drug's data. Third, and most relevant if you're using a telehealth or compounded provider: neither the brand confusion nor the manufacturer's marketing changes what the underlying molecule does — see our semaglutide vs. tirzepatide comparison for how the two molecules actually differ from each other in trial results, side effects, and cost.

Where compounded fits in

Compounded pharmacies prepare semaglutide or tirzepatide directly rather than dispensing a manufacturer's finished pen, so the Ozempic/Wegovy or Mounjaro/Zepbound brand distinction doesn't apply to what you receive — you're getting the molecule itself, not a specific FDA-approved product, indication label, or dose form. That has real trade-offs worth understanding before you compare pricing; see compounded vs. brand-name GLP-1 and is compounded GLP-1 legit and safe.

The takeaway

If a provider or a plan tells you "no" to Wegovy or Zepbound but "yes" to Ozempic or Mounjaro, ask directly why, and know that pharmacologically it's the identical active drug — the difference is the FDA-reviewed indication, the labeled dose, and often the price and coverage attached to that indication. Knowing which brand (or compounded equivalent) you're actually being offered, and why, is core to comparing providers honestly — something our quiz and comparison hub are built to make transparent rather than confusing.

Frequently asked questions

Are Ozempic and Wegovy the same drug?

Yes — both contain semaglutide from the same manufacturer, Novo Nordisk. Ozempic is approved for type 2 diabetes (and related cardiovascular/kidney risk reduction); Wegovy is approved for chronic weight management, cardiovascular risk reduction in obesity, and MASH. The molecule is identical; the approved use and labeled dose differ.

Are Mounjaro and Zepbound the same drug?

Yes — both contain tirzepatide from Eli Lilly. Mounjaro is approved only for type 2 diabetes. Zepbound is approved for chronic weight management and, as a newer indication, for moderate to severe obstructive sleep apnea in adults with obesity.

Why would a doctor prescribe Ozempic instead of Wegovy for weight loss?

Usually insurance: plans are more likely to cover Ozempic under a type 2 diabetes diagnosis than Wegovy under a weight-loss-only diagnosis, so some clinicians prescribe the diabetes-branded version off-label for weight management. Pharmacologically it's the same drug.

Does the brand matter if I get compounded semaglutide or tirzepatide?

The Ozempic/Wegovy or Mounjaro/Zepbound distinction is a manufacturer branding and FDA-indication difference, not a different molecule — so it doesn't apply the same way to compounded medication, which delivers the active drug itself rather than a specific finished, FDA-approved product.

References

  1. U.S. Food and Drug Administration (2026). Ozempic (semaglutide) injection — Prescribing Information (label). FDA / DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. U.S. Food and Drug Administration (2026). Wegovy (semaglutide) injection — Prescribing Information (label). FDA / DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. U.S. Food and Drug Administration (2026). Mounjaro (tirzepatide) injection — Prescribing Information (label). FDA / DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  4. U.S. Food and Drug Administration (2026). Zepbound (tirzepatide) injection — Prescribing Information (label). FDA / DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading